Novo slumps, Lilly gains on trial data results

Novo slumps, Lilly gains on trial data results

Investing.com — Shares of Novo Nordisk (NYSE:NVO) plummeted over 19% in premarket trading Friday after the results from its phase 3 trial of CagriSema, its next-generation obesity drug, disappointed. Meanwhile, rival…